1 - 5 of 5 articles
Radiotherapy (RT) has demonstrated synergy with immune checkpoint blockade (ICB) in preclinical models. However, its potential as an immunoadjuvant is limited by low immunogenicity at low radiation doses and immunosuppression at high radiation doses. It is hypothesized that radiosensitizers can...
Micheliolide (MCL) is a naturally occurring sesquiterpene lactone that selectively targets leukemic stem cells (LSCs), which persist after conventional chemotherapy for myeloid leukemias, leading to disease relapse. To overcome modest MCL cytotoxicity, analogs with ≈two–threefold greater...
Acquired resistance (AR) resulted from stimulated expression of AR‐related genes such as CD38 in activated T cells jeopardizes anti‐programmed death‐1 (anti‐PD‐1) immunotherapy. It remains to be explored whether the suppression of AR genes in activated T cells during anti‐PD‐1 therapy is able to...
Bone is a highly dynamic tissue. Hence, diseases affecting bone tissue, such as cancer (primary tumors and metastases), osteoporosis, and genetic conditions present many challenges for traditional therapies, leading to poor therapeutic outcome. Nano‐delivery systems are innovative tools used for...
Arthritis is a leading cause of disability in adults, which can be intensely incapacitating. The location and intensity of the pain is both subjective and challenging to manage. Consequently, patient‐directed delivery of anti‐inflammatories is an essential component of future therapeutic...
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Sign Up Log In
To subscribe to email alerts, please log in first, or sign up for a DeepDyve account if you don’t already have one.
To get new article updates from a journal on your personalized homepage, please log in first, or sign up for a DeepDyve account if you don’t already have one.